Trial · NCT00584935
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
NCT00584935, Phase 1, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2011-04-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid. Trials, record NCT00584935. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00584935
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
- NCT number
- NCT00584935
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Ocular Cicatricial Pemphigoid
- Interventions
- Rituximab
- First posted
- 2008-01-02
- Last updated
- 2026-05-04
- Results first posted
- 2011-04-21
- Limitations and caveats
- Genentech closed trial before site was able to enroll 5 patients.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks | 16 weeks | Stages Characteristics I Subconjunctival scarring and fibrosis II Fornix foreshortening (a-d describes % loss of inferior fornix depth) 1. 0-25% 2. 25-50% 3. 50-75% 4. 75-100% III Presence of symblepharon and number (n) (a-d describes % of horizontal involvement by symblepharons and n is the number of symblepharons countable) a. 0-25% b. 25-50% c. 50-75% d. 75-100% IV Ankyloblepharon, frozen globe |
| Primary | 2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits. | 16 weeks | |
| Secondary | 1. Stability of Visual Acuity (Snellen's Test) at 16 Weeks | 16 weeks | |
| Secondary | 2. Stability of Visual Acuity (Snellen's Test) at 24 Weeks | 24 weeks |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks | 16 weeks | The data for this Outcome was not collected and due to the length of time, the records have been destroyed. | ||
| PRIMARY | 2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits. | 16 weeks | The data for this Outcome was not collected and due to the length of time, the records have been destroyed. | ||
| SECONDARY | 1. Stability of Visual Acuity (Snellen's Test) at 16 Weeks | 16 weeks | The data for this Outcome was not collected and due to the length of time, the records have been destroyed. | ||
| SECONDARY | 2. Stability of Visual Acuity (Snellen's Test) at 24 Weeks | 24 weeks | The data for this Outcome was not collected and due to the length of time, the records have been destroyed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab | 3 | |
| Overall Study | COMPLETED | Rituximab | 3 | |
| Overall Study | NOT COMPLETED | Rituximab | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab | ||
| Total, other adverse events | Rituximab | 0 | 3 |
| Total, serious adverse events | Rituximab | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00584935
GET https://conductscience.org/api/trials/v1/NCT00584935/registered